Key result
Aldosterone synthase inhibitors improve BP control and lower albuminuria, potentially reducing residual cardiorenal risk.
Why the study?
Do aldosterone synthase inhibitors reduce residual risk in patients with cardiovascular and kidney disease?
Do aldosterone synthase inhibitors reduce residual risk in patients with cardiovascular and kidney disease?
Aldosterone synthase inhibitors are an emerging class of drugs that may further reduce residual cardiorenal risk beyond standard RAAS blockade.
Supports ongoing development of aldosterone synthase inhibitors; leaves open impact on hard cardiorenal endpoints pending phase III data.
Renin-angiotensin-aldosterone system (RAAS) blockade has been a mainstay of therapy in cardiovascular and kidney disease for nearly 30 years. Despite the development of multiple drug classes designed to intervene along the RAAS pathway, the residual risk for the totality of adverse cardiorenal outcomes (cardiorenal disease) remains substantial. Dysregulation of aldosterone biosynthesis has pathophysiological consequences that are associated with cardiovascular and kidney damage. Aldosterone synthase inhibitors (ASi) provide a mechanism to decrease aldosterone production. These agents may help to reduce residual risk in cardiorenal disease. Preliminary evidence from ASi clinical trials is encouraging, with demonstrated efficacy in improving blood pressure control and decreasing albuminuria in chronic kidney disease. Their therapeutic potential in improving cardiorenal outcomes is being investigated further in ongoing phase III trials where ASi agents are given as monotherapy or with an SGLT2 inhibitor, and these data will be available over the coming months and years. ASi agents may be a new evidence-based addition to the cardiorenal drug armamentarium.
No takes yet. Share an insight, caveat, or question.
Umanath et al. (2026) conducted a review in Cardiovascular and renal diseases. Aldosterone synthase inhibitors was evaluated. Aldosterone synthase inhibitors demonstrate efficacy in improving blood pressure control and decreasing albuminuria, offering a potential new mechanism to reduce residual cardiorenal risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: